Sarepta Therapeutics, Inc. SRPT R3KPHARMA
Company Overview
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, siRNA platform, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 45 skipping; and ELEVIDYS, an AAV-based gene therapy, which is contraindicated in patients with any deletion in exon 8 and/or exon 9 in the Duchenne gene. The company also develops SRP-9003, a gene therapy program for the treatment of LGMD2E; SRP-1001 to selectively target and knockdown DUX4 using RNAi in Phase 1/2a clinical trials; and SRP-1003 for reduction of expression of the DMPK gene in Phase 1/2a clinical trials. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Arrowhead Pharmaceuticals, Inc.; University of Western Australia; Nationwide Children's Hospital; Hansa Biopharma; and Duke University. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.
Why Investors Should Care
Revenue has grown at a 71.9% CAGR over the past five years.
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Dec 2025 Revenue of $2.20B (+15.6% YoY); net profit $-713.41M.
- Trailing 12 Months Year-on-year growth — revenue -34.3%, earnings -403.3%.
- 5-Year Trend Long-term compounding — revenue CAGR 71.9%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 71.90% |
| 1 Year: | -34.30% |
Compounded Profit Growth
| 5 Years: | - |
| 1 Year: | -403.27% |
Stock Price Performance
| 1 Year: | +2.65% |
| 6 Months: | +18.71% |
| 3 Months: | +34.66% |
| 1 Month: | +24.79% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)57.10 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 71.9% over 5 years.
- Generates positive free cash flow.
CONS
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | SRPT Sarepta Therapeutics, Inc. R3KPHARMA | 20.94 | -13.34 | $2.21B | 0.00% | -29.18% | -9.48% | 71.90% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Dec 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | 16.34M | 35.01M | 45.95M | 57.28M | 64.60M | 73.53M | 78.49M | 84.42M | 87.01M | 94.67M | 99.04M | 100.11M | 100.45M | 111.34M | 121.43M | 122.64M | 124.93M | 141.84M | 166.91M | 188.82M | 211.24M | 207.77M | 231.50M | 238.99M | 309.32M | 359.48M | 360.55M | 429.77M | - | 744.86M | 611.09M | 399.36M | 442.93M | 730.80M | 328.69M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 137.56M | 152.56M | 150.78M | 398.71M | 108.77M | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 308.93M | 316.00M | 338.08M | - | 607.29M | 458.53M | 248.58M | 44.23M | 622.03M | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 907.68M | 342.96M | 311.46M | 454.31M | 263.60M | - |
| Operating Income | -64.45M | -59.70M | -62.10M | -56.53M | -88.39M | -39.24M | -63.34M | -45.91M | -23.15M | -30.74M | -103.43M | -70.10M | -139.36M | -76.39M | -275.37M | -123.59M | -230.22M | -118.03M | -138.35M | -137.07M | -170.72M | -151.87M | -167.57M | -34.46M | -86.88M | -211.13M | -131.35M | -138.09M | -133.52M | -20.84M | 34.91M | -701.00K | 22.20M | - | -300.39M | 115.58M | -62.88M | -410.08M | 358.43M | 13.29M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -369.04M | 169.71M | -168.03M | -252.20M | 375.48M | - |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 4.50M | 5.23M | 7.57M | 20.84M | 21.71M | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -383.52M | 153.64M | -194.05M | -278.30M | 343.17M | - |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 63.99M | -43.25M | -14.10M | 4.55M | 12.21M | - |
| Net Income | -64.68M | -59.77M | -62.30M | -56.74M | -88.45M | 84.09M | -63.05M | -47.73M | -24.00M | -35.36M | -109.27M | -76.39M | -140.90M | -76.64M | -276.40M | -126.33M | -235.70M | -17.49M | -150.82M | -196.50M | -189.32M | -167.25M | -81.41M | -48.14M | -105.03M | -231.48M | -257.74M | -516.75M | -23.94M | -40.94M | 36.12M | 6.46M | 33.61M | - | -447.51M | 196.89M | -179.95M | -282.85M | 330.96M | -4.89M |
| Diluted EPS | - | -1.31 | -1.35 | - | - | 1.50 | -1.15 | -0.78 | -0.37 | -0.55 | -1.67 | - | - | - | - | - | - | - | - | - | - | - | -1.02 | -0.60 | -1.20 | -2.65 | -2.94 | -5.86 | -0.27 | -0.46 | 0.37 | 0.07 | 0.34 | - | -4.60 | 1.89 | -1.80 | -3.93 | 2.88 | -0.05 |
| R&D Expense | 41.38M | 38.83M | 44.35M | 34.35M | 70.75M | 29.12M | 58.91M | 34.24M | 44.44M | 46.20M | 122.85M | 86.58M | 146.21M | 90.55M | 113.27M | 133.95M | 223.14M | 136.14M | 188.52M | 190.44M | 207.24M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | 9.76M | 1.25M | 5.42M | 154.58M | 301.03M | 380.83M | 455.87M | - | 933.01M | 1.24B | 1.90B | 2.20B |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | 139.99M | 150.34M | 319.10M | 839.61M |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | 793.02M | 1.09B | 1.58B | 1.36B |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.33B | 1.36B | 1.36B | 2.02B |
| Operating Income | -15.51M | -20.93M | -35.93M | -29.70M | -90.28M | -133.79M | -220.18M | -266.73M | -171.64M | -343.63M | -705.56M | -564.16M | - | -536.20M | -267.82M | 218.08M | -657.77M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | -594.85M | -453.69M | 316.89M | -619.56M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | 53.25M | 22.01M | 18.39M | 38.14M |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | -689.96M | -520.10M | 260.77M | -702.23M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | 13.53M | 15.88M | 25.54M | 11.19M |
| Net Income | -25.16M | -32.18M | -2.32M | -121.29M | -111.98M | -135.79M | -220.03M | -267.26M | -50.69M | -361.92M | -715.08M | -554.13M | - | -703.49M | -535.98M | 235.24M | -713.41M |
| Diluted EPS | -0.27 | -0.29 | -0.02 | - | - | - | - | - | - | - | - | -7.11 | - | -8.03 | -5.80 | 2.34 | -7.13 |
| R&D Expense | 24.40M | 35.97M | 66.86M | 52.40M | 72.91M | 94.23M | 146.39M | 188.27M | 166.71M | 401.84M | - | - | - | - | - | - | - |
Balance Sheet (Annual)
Figures in USD.
| Metric | Jul 1980 | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Sep 2025 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | - | 45.98M | 54.37M | 204.99M | 291.57M | 295.03M | 273.78M | 424.10M | 1.31B | 1.64B | 1.82B | 2.98B | - | 3.13B | 3.26B | 3.96B | - | 3.35B |
| Current Assets | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 2.56B | 2.58B | 3.07B | - | 2.54B |
| Cash & Equivalents | 0 | 11.19M | 48.27M | 33.59M | 39.90M | 187.66M | 256.96M | 73.55M | 80.30M | 122.42M | 599.69M | 370.83M | 835.08M | 1.50B | - | 966.78M | 428.43M | 1.10B | - | 801.28M |
| Inventory | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 203.97M | 322.86M | 749.96M | - | 914.74M |
| Receivables | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 214.63M | 400.33M | 601.99M | - | 398.23M |
| Total Liabilities | - | - | - | - | - | 81.31M | 44.38M | 47.38M | 83.44M | 87.41M | 518.75M | 609.80M | 1.00B | 2.22B | - | 2.74B | 2.41B | 2.44B | - | 2.21B |
| Current Liabilities | - | - | - | 45.86M | 20.60M | 78.89M | 35.97M | 36.87M | 62.29M | 75.42M | 88.33M | 173.69M | 264.77M | 416.03M | - | 619.60M | 653.66M | 731.68M | - | 1.10B |
| Long Term Debt | - | - | - | 1.84M | 1.76M | 1.67M | 1.58M | 1.48M | 26.84M | 17.67M | 431.05M | 420.55M | - | - | - | 1.54B | 1.13B | 1.14B | 140.50M | 828.97M |
| Total Debt | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.62B | 1.40B | 1.34B | - | 1.04B |
| Total Equity | 0 | 15.73M | 23.63M | -2.82M | 31.02M | 123.68M | 247.19M | 247.65M | 190.35M | 336.69M | 789.22M | 1.03B | 818.19M | 761.76M | - | 384.95M | 859.34M | 1.53B | - | 1.14B |
| Shares Outstanding | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 87.95M | 93.73M | 96.90M | - | 105.62M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -8.80M | -15.21M | -23.68M | -29.69M | -64.69M | - | - | -245.82M | -232.00M | -388.66M | -456.46M | 107.47M | - | -325.35M | -500.99M | -205.79M | -205.48M |
| Investing Cash Flow | -1.88M | -1.96M | -2.31M | -1.15M | -11.67M | - | - | -90.19M | -178.81M | -370.49M | 286.73M | -121.72M | - | -1.05B | -165.80M | 755.56M | 69.64M |
| Financing Cash Flow | 47.77M | 2.48M | 32.30M | 178.60M | 145.67M | - | - | 378.13M | 888.08M | 530.15M | 642.55M | 682.32M | - | 232.51M | 125.00M | 124.81M | -168.34M |
| Capital Expenditure | -931.00K | -832.00K | -1.18M | -108.00K | -2.37M | -25.44M | -3.40M | -5.34M | -12.00M | -61.16M | -59.63M | -82.20M | - | -32.25M | -87.34M | -146.96M | -109.85M |
| Free Cash Flow | -9.73M | -16.04M | -24.86M | -29.80M | -67.06M | - | - | -251.16M | -244.00M | -449.82M | -516.09M | 25.26M | - | -357.60M | -588.34M | -352.74M | -315.33M |
| Net Change in Cash | - | - | - | - | - | - | - | - | - | - | - | - | - | -1.14B | -541.79M | 674.58M | -304.18M |
| Share Buybacks | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 0 | 25.01M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - | 85.0% | 87.9% | 83.2% | 61.8% |
| Operating Margin % | - | - | - | - | - | -1,371.2% | -17,572.5% | -4,920.3% | -111.0% | -114.1% | -185.3% | -123.8% | - | -57.5% | -21.5% | 11.5% | -29.9% |
| Net Margin % | - | - | - | - | - | -1,391.7% | -17,560.3% | -4,930.2% | -32.8% | -120.2% | -187.8% | -121.6% | - | -75.4% | -43.1% | 12.4% | -32.5% |
| ROE % | -106.5% | 1,142.2% | -7.5% | -98.1% | -45.3% | -54.8% | -115.6% | -79.4% | -6.4% | -35.1% | -87.4% | -72.7% | - | -182.7% | -62.4% | 15.4% | -62.5% |
| ROCE % | - | -17,591.6% | -106.4% | -23.6% | -35.3% | -51.8% | -104.1% | -76.5% | -14.1% | -23.4% | -45.3% | -22.0% | - | -21.4% | -10.3% | 6.7% | -29.2% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Blackrock Inc. | 17.98% | 18.99M | $381.99M |
| 2 | State Street Corporation | 8.44% | 8.92M | $179.30M |
| 3 | Vanguard Portfolio Management LLC | 7.93% | 8.38M | $168.47M |
| 4 | Vanguard Capital Management LLC | 4.35% | 4.59M | $92.34M |
| 5 | Two Sigma Investments, LP | 4.35% | 4.60M | $92.48M |
| 6 | First Trust Advisors LP | 4.13% | 4.37M | $87.80M |
| 7 | AQR Capital Management, LLC | 4.10% | 4.33M | $86.99M |
| 8 | Geode Capital Management, LLC | 2.62% | 2.77M | $55.74M |
| 9 | Erste Asset Management GmbH | 2.43% | 2.57M | $51.66M |
| 10 | Marshall Wace LLP | 2.09% | 2.21M | $44.36M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for SRPT
$SRPT stock is down 11% today. Here's what we see in our data. - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMiogFBVV95cUxPRjhjWkVXOVRWUG1YT2xDZTZ5MGdicTlnTV9uT1o5c0plaUJraUFPVGhueFI4LWR3REFZRUdkZkUtaExZQUtDYlEwd3ljMVNDempnRjVEVE9vV0RMRGd4VW5HQTROdnl5SWp6c1o3OWlza0V6bDJYQzBPMWhvRXVhbkIzV1BYZFROMW5uVn…
Twenty students living with Duchenne and five siblings receive up to $5,000 for college - Stock Titan
<a href="https://news.google.com/rss/articles/CBMivgFBVV95cUxQckVaOElUTlZQSjdYdG1kN1hpQ3o0VGFDQXdZOVc1TnBVMmI5LUNKbWdIUTZuZ1htc3BPWGVkZmVhRk1Rd3BFZjNuanZYQkZTMGVpcVdnSW5zVGhSTkNJbmZXNVZLQXhJVmg0RjBuX3F5cjVBVHhydmpnd0sxaTZJMFZfaWMwUnhBcG5HMn…
Sarepta Therapeutics Stock Price Forecast. Should You Buy SRPT? - StockInvest.us
<a href="https://news.google.com/rss/articles/CBMiSEFVX3lxTE9rWFlPQkJucXdCVzBUMXFqMlRKZkJZMnN6T3RuTFdYZzBoSFpsOXdVTHEzUUV2VzBpaWZVS0dRUXJPMVhVeTMxaw?oc=5" target="_blank">Sarepta Therapeutics Stock Price Forecast. Should You Buy SRPT?</a>&n…
NVS Stock Clocks Worst Day In Over 20 Years After Second Trial Failure In A Week — DYN, SRPT Slip In Sympathy - finance.yahoo.com
<a href="https://news.google.com/rss/articles/CBMikAFBVV95cUxQQkNKSXplM045WUZhbTk2MFdOODF5V3k4eGVRdWZTUkktdkZ1TWxWbENfblV0dEtNWWZObGE2cG9LTXZUbkdGcDBPSjZSU21PLTRpVnNMeVA5V1pGelEwYzdZa2JXcWlBaTBGREx2VmNpMGx0RVV4cXQwREtpU2tFckxhTklBQTJQNTljR1…
This Analyst Sees 34% Upside For SRPT Stock — Here's Why They Expect A Sustained Rally Next - Stocktwits
<a href="https://news.google.com/rss/articles/CBMixgFBVV95cUxPejRzbXc3VzdveE9MY1ZvR2QxYmFIdVFBSXFYRmVoaFdGX0VqSk01bFZ2d2RNQWpHRnEwVVVRM25TZURWMDBQR2x6NjkzbV9XbUM1V2JHbmZxdi1pckpHZUVJVTVqb2NkLTV0Z1l5WV9vWlFnZ0N1RXJITUlUZkNJUUx0OWxaTVZMeWJ1al…
A Rivals Clinical Stumble Sends Sarepta Therapeutics Stock Lower - Benzinga
<a href="https://news.google.com/rss/articles/CBMirgFBVV95cUxQU0V6a1hKTnU5aHBLLWpKRWExNE11VTl6Xy0xV292MTRKR1llR3lOZ1NsaTFQanhpSG5qaHN5WjI5WGNIcmlvTTRmUE9XMmtLSHRBSWxQcGl2NHk3SmxWZHB6bHUtdV94NkIyc2J4MUxCeVNsajRGMzJ6amhILVk0anhsSnQ5bnVWV3BpZk…
SRPT — Frequently Asked Questions
What is the current share price of Sarepta Therapeutics, Inc. (SRPT)?
As of 2026-09-19 21:16 PDT, Sarepta Therapeutics, Inc. (SRPT) trades at $20.94 on NasdaqGS. Its 52-week range is $14.86 to $24.45.
What is the market capitalisation of SRPT?
Sarepta Therapeutics, Inc. (SRPT) has a market capitalisation of $2.21B on NasdaqGS.
What is the P/E ratio of SRPT?
SRPT trades at a trailing price-to-earnings (P/E) ratio of -13.34. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 1.39.
What is the return on equity (ROE) of SRPT?
SRPT has a return on equity (ROE) of -9.48%. Its return on capital employed (ROCE) is -29.18%.
Is SRPT a good stock to buy?
This page provides a data-driven analysis of Sarepta Therapeutics, Inc. (SRPT), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.